| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Harmony Biosciences Holdings, Inc.'s insiders have reduced their positions by a net 72,406 shares worth roughly $3.1M.
Counted by filing, the last 12 months brought no open-market purchases and 7 sales by 3 insiders worth about $6.0M. The 12 months before that brought no open-market purchases and 10 sales by 3 insiders worth about $5.4M.
5 of the 7 sales in the last 12 months were made under a Rule 10b5-1 trading plan; the rest were not.
No insider has bought HRMY shares in the open market in the last two years. The last purchase on record was by Jack Nielsen on August 25, 2020.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 24.5K | $907.8K | - | |
| Other | 13.1K | $485.5K | - | |
| CEO | 7.3K | $271.9K | - | |
| Other | 4.3K | $160.2K | - | |
| Other | 1.5K | $54.6K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Kumar Budur | Chief Medical Officer | Sale+OE | 38,452 | $43.05 | $1,655,416.21 | -74.6% | - | - | |
| Sep 8, 2026 | Kumar Budur | Chief Medical Officer | Sale+OE | 33,954 | $42.80 | $1,453,169.44 | -72.1% | - | - | |
| Jan 26, 2026 | Sandip Kapadia71 | Chief Financial Officer | Sell10b5-1 | 3,746 | $37.15 | $139,171.39 | -13.3% | -16.9% | - | |
| Jan 15, 2026 | Sandip Kapadia71 | Chief Financial Officer | Sell10b5-1 | 20,961 | $35.92 | $752,833.18 | -100% | -19.7% | - | |
| Dec 12, 2025 | Jeffrey M. Dayno54 | President, CEO | Sale+OE10b5-1 | 25,933 | $40.11 | $1,040,102.61 | - | -31.4% | - | |
| Dec 5, 2025 | Sandip Kapadia71 | Chief Financial Officer | Sale+OE10b5-1 | 20,000 | $39.54 | $790,896.00 | - | -28.4% | - | |
| Nov 21, 2025 | Sandip Kapadia71 | Chief Financial Officer | Sell10b5-1 | 3,427 | $35.00 | $119,945.00 | -100% | +0.2% | - | |
| Aug 15, 2025 | Sandip Kapadia71 | Chief Financial Officer | Sell10b5-1 | 21,573 | $36.50 | $787,377.83 | -100% | -7.0% | +3.4% | |
| Apr 1, 2025 | Sandip Kapadia71 | Chief Financial Officer | Sell10b5-1 | 6,987 | $32.54 | $227,385.94 | -100% | -2.5% | -13.8% | |
| Mar 3, 2025 | Jeffrey Dierks62 | Chief Commercial Officer | Sale+OE10b5-1 | 4,869 | $32.67 | $159,089.50 | - | +10.5% | -12.1% |